All‐cause mortality
All‐cause mortality
0.14 [0, 6.98]
8 studies · 2175 participants
Moderate
Peto OR 1.06 [0.62, 1.82]
14 studies · 6173 participants
Low
All‐cause mortality
1 finding from 1 review
All‐cause mortality
1 finding from 1 review
All‐cause mortality
It is very uncertain whether summary of findings: insulin degludec changes all‐cause mortality compared with insulin glargine (very low certainty).
1 finding from 1 review
All‐cause mortality · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
All‐cause mortality · people with cancer with VTE receiving secondary prophylaxis
Idraparinux secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Coronary heart disease mortality – CHD deaths · adults with or without existing CVD
High showed no clear difference in coronary heart disease mortality – CHD deaths compared with low long‐chain omega‐3 fats (low certainty).
1 finding from 1 review
Intervention not reported
Mortality (6 months) · older adults with functional dependence
It is very uncertain whether the intervention changes mortality (6 months) (very low certainty).
1 finding from 1 review
Cardiovascular mortality · adults with or without existing CVD
High probably leads to lower cardiovascular mortality – cardiovascular deaths compared with low long‐chain omega‐3 fats (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · stable COPD
Triple therapy may leads to lower mortality (all‐cause) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
It is very uncertain whether once‐daily ICS/LABA combined inhalers changes mortality (all‐cause) compared with once‐daily LAMA (very low certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
Tiotropium + LABA/ICS combination showed no clear difference in mortality (all‐cause) compared with tiotropium (moderate certainty).
1 finding from 1 review
ICU mortality · all conditions
Transfusion of RBCs of shorter showed no clear difference in mortality: in‐ICU mortality compared with standard practice storage duration (moderate certainty).
1 finding from 1 review
Mortality Duration of 18 months3 · COPD
Combined inhalers probably leads to lower mortality Duration of 18 months3 compared with placebo (primary outcomes) (moderate certainty).
1 finding from 1 review
All‐cause mortality (time‐to‐event) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Mortality from any cause (all doses) · postmenopausal women with or without vasomotor symptoms
Tibolone showed no clear difference in mortality from any cause (all doses) compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality (3‐week to 1‐year · Adults with COPD
Once‐daily LABA/LAMA in a combined inhaler showed no clear difference in all‐cause mortality (3‐week to 1‐year compared with placebo (low certainty).
1 finding from 1 review
Mortality from any cause (tibolone 2.5 mg/d) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes mortality from any cause (tibolone 2.5 mg/d) compared with combined HT (very low certainty).
1 finding from 1 review